Clinical Trials Logo
  1. Home
  2. Meningioma
  3. NCT06278103
  4. Details
NCT06278103 Clinical Trial

Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas (MethylRH-M)

Meningioma Clinical Trial

— MethylRH-M  

Official title:
Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT06278103
Other study ID # 2023PI113
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 1, 2000
Est. completion date September 1, 2024

Study information
Verified date February 2024
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This research aims to explore the relationship between hormonal receptor expression and the clinical and histopathological characteristics of meningiomas. The underlying hypothesis is that hormonal receptor expression, as well as the methylation profile of their gene promoters, are associated with specific aspects of meningiomas and patients' clinical outcomes. The main objective is to study the correlation between the immunohistochemical expression of hormonal receptors and clinicopathological data. The secondary objectif is to study the correlation between the methylation profile of hormonal receptor gene promoters and their immunohistochemical expression.

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 180
Est. completion date September 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who underwent surgery for a meningioma at the University Hospital of Nancy between 2000 and 2022. Exclusion Criteria: - Patients who did not express their consent to participate in the study. - Patients with grade 2 or 3 meningiomas whose samples are no longer available or in insufficient quantity to perform an immunohistochemical study. - Patients with grade 1 meningiomas not selected by randomization. - Patients withdrawing their consent.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Central Hospital, Nancy, France

Outcome
Type Measure Description Time frame Safety issue
Primary immunohistochemical expression of different hormonal receptors Evaluated on FFPE sections up to 24 years after surgery
Secondary methylation profile of the promoters of hormonal receptor genes Methylation profile established from frozen tissue. up to 24 years after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Recruiting NCT03631953 - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Completed NCT01811524 - The Etiology and Progression of Brain Tumors N/A
Completed NCT03648034 - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality N/A
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Recruiting NCT06014905 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma Phase 1
Not yet recruiting NCT04386642 - Tranexamic Acid Reduce Blood Loss in Meningioma Resection Phase 4
Active, not recruiting NCT04595786 - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection N/A
Active, not recruiting NCT04305470 - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Phase 3
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Not yet recruiting NCT02978677 - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas N/A
Active, not recruiting NCT02933736 - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Early Phase 1
Completed NCT02267928 - Information Presentation Formats N/A
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Active, not recruiting NCT03071874 - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Phase 2
Recruiting NCT05416567 - Embolization for Meningioma N/A